Physician profile
Keyla Gammarano
NPI 1497390173
$9,665.43
in general payments reported to CMS, 2019-2025
8 companies · $964 in 2025
The $964 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $64.49 · 2021: $1,134 · 2022: $1,068 · 2023: $4,087 · 2024: $2,349 · 2025: $964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,970 · Travel and Lodging: $3,095 · Entertainment: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,969.60 |
| Travel and Lodging | $3,094.89 |
| Entertainment | $334.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $3,406.61 | 2020-2025 | Cvi Contact Lens, Clariti Contact Lens, Myday Contact Lens |
| Alcon Vision LLC | $2,692.86 | 2021-2025 | Total30, Precision7, Precision 1 |
| Johnson & Johnson Vision Care, INC. | $1,967.52 | 2022-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $832.92 | 2022-2025 | Infuse, Miebo |
| Optos, INC. | $475.04 | 2022-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Biotissue Holdings INC. | $143.32 | 2023 | |
| Allergan, INC. | $102.77 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $44.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keyla Gammarano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.